Gilead Sciences to Present at the 22nd Annual Piper Jaffray Healthcare Conference on Tuesday, November 30

Webcast Available Through Gilead Corporate Website

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 22nd Annual Piper Jaffray Healthcare Conference in New York.

John F. Milligan, PhD, Gilead’s President and Chief Operating Officer, will provide an overview of the company on Tuesday, November 30 at 9:30 a.m. Eastern Standard Time.

To access the live webcast via the Internet log on to www.gilead.com. Please connect to the company’s website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).



CONTACT:

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investor Relations)

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.